Earnings Release
Cipla Reports FY26 Results with Record Revenue; Final Dividend of ₹13 per Share Recommended
NSE
cipla
BSE
500087
Cipla Limited reported audited FY26 consolidated revenue of ₹28,163 crore, up 2% YoY, while EBITDA stood at ₹5,925 crore. The company delivered strong growth in India and Africa markets despite weakness in North America. The Board recommended a final dividend of ₹13 per equity share for FY26.
PRICE-SENSITIVE TRIGGER
Event: Q4 FY26 and FY26 Audited Financial Results
Type: Earnings Release
Impact: Neutral
Immediate Effect: Strong India and Africa growth supported annual performance, though pressure in North America and lower profitability impacted margins and PAT during Q4 and FY26.
Key Metrics:
- FY26 Revenue: ₹28,163 Cr (+2% YoY)
- FY26 EBITDA: ₹5,925 Cr
- FY26 EBITDA Margin: 21.0%
- FY26 PAT: ₹3,879 Cr
- Q4 FY26 Revenue: ₹6,541 Cr (-3% YoY)
- Q4 FY26 EBITDA: ₹997 Cr
- Q4 FY26 PAT: ₹555 Cr
- Final Dividend Recommended: ₹13 per equity share
- Net Cash Position: ₹10,526 Cr
Highlight:
- Label: FY26 Revenue
- Value: ₹28,163 Cr
What Happened ?
Cipla Limited announced its audited consolidated financial results for Q4 FY26 and FY26.
The company reported FY26 revenue growth of 2% YoY to ₹28,163 crore, driven by strong performance in India and Africa businesses. EBITDA for FY26 stood at ₹5,925 crore with EBITDA margin of 21.0%, while PAT came at ₹3,879 crore.
For Q4 FY26, revenue declined 3% YoY to ₹6,541 crore, while EBITDA and PAT fell to ₹997 crore and ₹555 crore respectively, mainly due to normalization in North America business and lower margins.
The Board recommended a final dividend of ₹13 per equity share for FY26, subject to shareholder approval.
key highlights
Business Performance & Operational Highlights:
- India business delivered strong 15% YoY growth in Q4 FY26.
- One India business crossed ₹12,500 crore annual revenue milestone in FY26.
- North America business generated annual revenue of US$780 million despite quarterly weakness.
- Cipla received USFDA approval for first AB-rated gVentolin product with CGT.
- One Africa business reported healthy 7% annual growth in USD terms.
- Emerging Markets and Europe business crossed US$400 million annual revenue milestone.
- R&D investments stood at ₹509 crore during Q4 FY26.
- Company maintained strong net cash position of ₹10,526 crore.
- USFDA inspections at Bengaluru, Navi Mumbai, and Goa facilities received “VAI” or “NAI” classification.
- Consumer Health brands Nicotex, Omnigel, and Cipladine maintained leadership positions.
Note:
- The company highlighted resilient India operations and continued global diversification despite pressure in certain international markets.
Risk Analysis
Key Risks
- North America revenue declined during Q4 FY26.
- EBITDA margin declined to 15.2% in Q4 FY26 from 22.8% last year.
- FY26 PAT declined compared to FY25 levels.
- US generic pricing pressure and regulatory risks remain key concerns.
- Currency fluctuations and geopolitical uncertainties may impact overseas businesses.
Worst Case Scenario
- Sustained pricing pressure in the US market, regulatory setbacks, or margin compression across global operations could impact future profitability and earnings growth.
Risk Level: Medium
Company Commentary
- Management stated FY26 marked Cipla’s highest-ever annual revenue.
- Cipla highlighted robust double-digit growth in key chronic therapies within India.
- The company emphasized continued expansion in differentiated portfolios across North America.
- Management reiterated focus on flagship brands, future pipeline investments, and regulatory compliance.
- Cipla stated that strong net cash position provides flexibility for long-term growth investments.
Official Exchange Filing: Cipla Limited